We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.63B
AUM Growth
-$171M
Cap. Flow
-$213M
Cap. Flow %
-13.08%
Top 10 Hldgs %
50.48%
Holding
102
New
12
Increased
17
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$101M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$28.5M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$21.2M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$14.3M
5
PETX
Aratana Therapeutics, Inc.
PETX
+$14M

Top Sells

Rank Stock Value
1
EBS icon
Emergent Biosolutions
EBS
+$33.1M
2
NVRO
NEVRO CORP.
NVRO
+$21.7M
3
CSII
Cardiovascular Systems, Inc.
CSII
+$19M
4
MASI
Masimo
MASI
+$16.3M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 78.51%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPNC
51
DELISTED
Spectranetics Corp
SPNC
$8.51M 0.52%
565,079
-335,170
-37% -$4.42M
ELOS
52
DELISTED
Syneron Medical Ltd
ELOS
$8.14M 0.5%
1,055,221
– –
AMRN
53
Amarin Corp
AMRN
$284M
$7.89M 0.49%
208,761
– –
ADMA icon
54
ADMA Biologics
ADMA
$1.92B
$7.78M 0.48%
964,193
– –
MRTX
55
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.45M 0.46%
235,870
-59,830
-20% -$2.11M
TNXP icon
56
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
VXRT
57
DELISTED
Vaxart
VXRT
$6.76M 0.42%
316,974
– –
CFRX
58
DELISTED
ContraFect Corporation
CFRX
$6.74M 0.41%
1,773
– –
TENX icon
59
Tenax Therapeutics
TENX
$385M
$6.46M 0.4%
62
– –
NVDQ
60
CALL
DELISTED
Novadaq Technologies Inc.
NVDQ
$6.37M 0.39%
+500,000
New +$5.98M
ARDX icon
61
Ardelyx
ARDX
$1.24B
$6.33M 0.39%
349,290
-200,000
-36% -$3.72M
ANTH
62
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.36M 0.33%
144,334
– –
PLXP
63
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$5.22M 0.32%
58,247
– –
AEGR
64
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$5.05M 0.31%
+500,000
New +$6.02M
SCYX icon
65
SCYNEXIS
SCYX
$37M
$4.81M 0.3%
9,688
– –
CASM
66
DELISTED
CAS Medical Systems, Inc.
CASM
$4.63M 0.29%
2,618,296
– –
BLRX
67
BioLineRX
BLRX
$12.3M
$4.55M 0.28%
5,833
– –
MDWD icon
68
MediWound
MDWD
$183M
$4.54M 0.28%
75,855
+3,059
+4% +$193K
GNCA
69
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.46M 0.27%
105,780
-25,000
-19% -$1.19M
OSUR icon
70
OraSure Technologies
OSUR
$273M
$4.42M 0.27%
685,528
– –
KALV
71
DELISTED
KalVista Pharmaceuticals
KALV
$4.27M 0.26%
84,210
– –
EPRS
72
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$4.25M 0.26%
1,375,000
+600,000
+77% +$2.7M
FATE icon
73
Fate Therapeutics
FATE
$281M
$3.75M 0.23%
1,113,986
– –
PLX icon
74
Protalix BioTherapeutics
PLX
$191M
$3.4M 0.21%
+333,857
New +$3.39M
TTNP
75
DELISTED
Titan Pharmaceuticals
TTNP
$3.38M 0.21%
+211
New +$3.44M
1 2
3
4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Broadfin Capital held 102 positions worth $1.63B, down 9.5% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital withdrew a net $213M in Q4 2015, closing 14 positions and reducing 20 holdings. Its most notable exit was Cardiovascular Systems, Inc., an estimated $19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 63% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Bausch Health worth $91.5M.

  • Broadfin Capital's largest Q4 2015 buy was Bausch Health: 900,000 shares worth $91.5M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $28.5M increase.
  • Broadfin Capital's biggest Q4 2015 reduction was Emergent Biosolutions, cutting an estimated $33.1M.
  • Broadfin Capital fully exited Cardiovascular Systems, Inc. in Q4 2015, selling an estimated $19M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.63B portfolio in Q4 2015.
  • Broadfin Capital opened 12 new positions and closed 14 in Q4 2015.
  • Broadfin Capital's portfolio value fell 9.5% quarter-over-quarter to $1.63B.

Based on Broadfin Capital's 13F filing for Q4 2015, filed 16 Feb 2016.